DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Motzer RJ. et al.
JAVELIN Renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC).
ESMO. 2018 abstr. LBA6_PR
Access:
We do not assume any responsibility for the contents of the web pages of other providers.